Cargando…

Low incidence of peripheral arterial disease in patients receiving dasatinib in clinical trials

Detalles Bibliográficos
Autores principales:	le Coutre, P D, Hughes, T P, Mahon, F-X, Kim, D-W, Steegmann, J L, Shah, N P, Gooden, K, Wallis, N, Cortes, J E
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2016
Materias:	Letter to the Editor
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4935977/ https://www.ncbi.nlm.nih.gov/pubmed/26686247 http://dx.doi.org/10.1038/leu.2015.352

Ejemplares similares

Evaluation of cardiovascular ischemic event rates in dasatinib-treated patients using standardized incidence ratios
por: Saglio, Giuseppe, et al.
Publicado: (2017)

Incidence, outcomes, and risk factors of pleural effusion in patients receiving dasatinib therapy for Philadelphia chromosome-positive leukemia
por: Hughes, Timothy P., et al.
Publicado: (2019)

Lymphocytosis after treatment with dasatinib in chronic myeloid leukemia: Effects on response and toxicity
por: Schiffer, Charles A., et al.
Publicado: (2016)

Isolated central nervous system blast crisis in a case of chronic myeloid leukemia on dasatinib
por: Kiran, P. K., et al.
Publicado: (2018)

In silico and preclinical drug screening identifies dasatinib as a targeted therapy for T-ALL
por: Laukkanen, S, et al.
Publicado: (2017)

Long-term use of dasatinib in patients with metastatic castration-resistant prostate cancer after receiving the combination of dasatinib and docetaxel
por: Araujo, John C, et al.
Publicado: (2013)

Optimal therapeutic strategy for those with chronic kidney disease and peripheral artery disease receiving peripheral vascular intervention
por: Imamura, Teruhiko
Publicado: (2020)

Atypical posterior reversible encephalopathy syndrome secondary to dasatinib
por: Nayak, Amiya Ranjan, et al.
Publicado: (2023)

B-lymphoid tyrosine kinase (Blk) is an oncogene and a potential target for therapy with dasatinib in cutaneous T-cell lymphoma (CTCL)
por: Petersen, D L, et al.
Publicado: (2014)

Insights into dasatinib use and outcomes in real-world patients with chronic myeloid leukemia
por: Adattini, Josephine A., et al.
Publicado: (2023)

The tyrosine kinase inhibitor dasatinib (SPRYCEL) inhibits chondrocyte activity and proliferation
por: Vandyke, K, et al.
Publicado: (2011)

Imatinib failure and response to dasatinib in a patient with chronic myeloid leukemia in blast crisis and a novel, nine-nucleotide BCR-ABL insertion mutation
por: Sigl, M, et al.
Publicado: (2013)

The EBF1-PDGFRB T681I mutation is highly resistant to imatinib and dasatinib in vitro and detectable in clinical samples prior to treatment
por: Tran, Thai Hoa, et al.
Publicado: (2021)

A Dasatinib-Induced Chylothorax Persisting After the Discontinuation of Dasatinib
por: Bradt, Nicolas, et al.
Publicado: (2022)

Exacerbation of pleural effusion in a dasatinib-treated patient during the perioperative period
por: Hasegawa, Takayuki, et al.
Publicado: (2022)

Dasatinib-induced reversible pulmonary arterial hypertension in a pediatric patient with BCR/ABL1+ lymphoblastic lymphoma from chronic myeloid leukemia
por: Han, Hye-ji, et al.
Publicado: (2022)

Dasatinib-Loaded Erythrocytes Trigger Apoptosis in Untreated Chronic Myelogenous Leukemic Cells: A Cellular Reservoir Participating in Dasatinib Efficiency
por: Airiau, Kelly, et al.
Publicado: (2018)

Incidence and Risk Factors for Breakthrough Invasive Mold Infections in Acute Myeloid Leukemia Patients Receiving Remission Induction Chemotherapy
por: Patel, Heena P, et al.
Publicado: (2019)

Phase I clinical trial of the Src inhibitor dasatinib with dacarbazine in metastatic melanoma
por: Algazi, A P, et al.
Publicado: (2012)

Dasatinib-Related Chylothorax
por: Huang, Yen-Min, et al.
Publicado: (2015)

DASATINIB-RELATED CHYLOTHORAX
por: Young, Katherine, et al.
Publicado: (2019)

Rapid clinical improvement of peripheral artery occlusive disease symptoms after nilotinib discontinuation despite persisting vascular occlusion
por: Maurizot, A, et al.
Publicado: (2014)

Asymptomatic peripheral artery disease in South Indian women with type 2 diabetis
por: Binu, M. G., et al.
Publicado: (2011)

Long lasting complete molecular remission after suspending dasatinib treatment in chronic myeloid leukemia
por: Gadó, Klára, et al.
Publicado: (2012)

Dasatinib induces severe hemorrhagic colitis in a patient with accelerated phase of chronic myelogenous leukemia
por: Yim, Eunjung, et al.
Publicado: (2018)

Reversible Pulmonary Arterial Hypertension Associated with Dasatinib for Chronic Myeloid Leukemia
por: Hong, Ji Hyung, et al.
Publicado: (2015)

Dasatinib-Induced Pulmonary Arterial Hypertension Treated with Upfront Combination Therapy
por: Nishimori, Makoto, et al.
Publicado: (2018)

Dasatinib-induced Nonspecific Interstitial Pneumonia That Developed 7 Years after the Initiation of Dasatinib
por: Takekoshi, Daisuke, et al.
Publicado: (2020)

Physicians’ attitude towards selection of second line therapy with nilotinib and dasatinib in chronic myeloid leukemia patients
por: Breccia, Massimo, et al.
Publicado: (2017)

Dasatinib enhances anti-leukemia efficacy of chimeric antigen receptor T cells by inhibiting cell differentiation and exhaustion
por: Zhang, Hao, et al.
Publicado: (2021)

Haemorrhagic Colitis Caused by Dasatinib
por: Patodi, Nishant, et al.
Publicado: (2012)

Dasatinib-induced Pulmonary Hypertension
por: Tamura, Yudai, et al.
Publicado: (2022)

Pulmonary arterial hypertension in a patient treated with dasatinib: a case report
por: Skride, Andris, et al.
Publicado: (2017)

Dasatinib-induced pulmonary arterial hypertension complicated with scleroderma: a case report
por: Toya, Takumi, et al.
Publicado: (2019)

Dasatinib-induced Reversible Demyelinating Peripheral Neuropathy and Successful Conversion to Nilotinib in Chronic Myelogenous Leukemia
por: Inoue, Hiroyasu, et al.
Publicado: (2020)

Dasatinib preferentially induces apoptosis by inhibiting Lyn kinase in nilotinib-resistant chronic myeloid leukemia cell line
por: Okabe, Seiichi, et al.
Publicado: (2011)

A Case of Dasatinib-Induced Nephrotic Syndrome in a Child with Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia
por: Lim, Young Tae, et al.
Publicado: (2016)

Predictive biomarkers for dasatinib treatment in melanoma
por: Eustace, Alex J., et al.
Publicado: (2014)

Increased Peripheral Arterial Calcification in Patients Receiving Warfarin
por: Han, Kum Hyun, et al.
Publicado: (2016)

Concomitant JAK2 V617F-positive polycythemia vera and BCR-ABL-positive chronic myelogenous leukemia treated with ruxolitinib and dasatinib
por: Zhou, A, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_un7839oqgtisd28uao7p7619o4